Perkovic V, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391:109–121. doi: 10.1056/NEJMoa2403347
Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024; 30:2058–2066. doi: 10.1038/s41591-024-03015-5
2023 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2023. https://usrds-adr.niddk.nih.gov/2023